Company Encyclopedia
View More
name
Compumedics Limited
CMP.AU
News
View More

Compumedics Secures Early FDA Approval and $2.15 Million for Somfit D Expansion

Compumedics Limited has received early FDA approval for its Somfit D product and raised $2.15 million to enhance its commercialization in the US home sleep testing market. The funds will support production and meet the growing demand for Somfit D and OrionMEG, positioning the company for a valuation re-rating. The latest analyst rating for Compumedics (AU:CMP) is a Hold with a price target of A$0.50. Compumedics specializes in sleep diagnostics and neuro-monitoring, focusing on the US market and global expansion.

Tip Ranks·
Tip Ranks·

Compumedics Limited Strengthens Corporate Governance Framework

Compumedics Limited (AU:CMP) has announced its commitment to enhancing corporate governance, highlighting the importance of the relationship between the Board and senior management for long-term success. The Board will focus on strategic guidance, financial oversight, and effective management processes to benefit shareholders and stakeholders. The latest analyst rating for AU:CMP is a Hold with a price target of A$0.50. Compumedics operates in the medical technology sector, specializing in diagnostic and monitoring equipment for healthcare providers.

Tip Ranks·
Tip Ranks·

Compumedics Limited Reports Strong Financial Outlook and Market Leadership

Compumedics Limited (AU:CMP) reported a strong financial outlook with FY25 revenue of $51 million and a forecast exceeding A$70 million for FY26, alongside an EBITDA of approximately A$9 million. The company leads in sleep and neuro diagnostics in Australia and Japan, is the top supplier in China, and ranks third in TCD devices in Germany and neurological monitoring in the USA. The latest analyst rating is a Hold with a price target of A$0.50. Compumedics, established in 1987, operates globally with over 30,000 systems installed.

Tip Ranks·
Tip Ranks·

Compumedics Secures $24M Distribution Agreements in China

Compumedics Limited has secured two 4-year distribution agreements in China worth A$24.4 million, focusing on sleep diagnostics and neurology. These agreements include a minimum 10% annual growth commitment and aim to enhance the company's presence in Northern and Eastern China. This strategic initiative is part of Compumedics' efforts to diversify its revenue streams and position itself for sustained growth in key international markets, particularly in Asia.

Tip Ranks·
Tip Ranks·

Compumedics Expands Market Presence with New Securities Quotation

Compumedics Limited (AU:CMP) has announced the application for the quotation of 178,572 fully paid ordinary securities on the ASX, effective November 19, 2024. This initiative aims to enhance the company's financial standing and market visibility, positively impacting operations and stakeholder interests. Compumedics specializes in medical technology, focusing on patient monitoring and diagnostic systems in sleep, brain, and blood-flow monitoring. The company has a current market cap of A$60.49M and a year-to-date price performance of 18.87%.

Tip Ranks·
Tip Ranks·